Uma Sinha

BridgeBio (United States) — United States

Medicine · Health Sciences

32h-index4.3kcitations149works18.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Coagulation and Thrombosis Mechanisms(46), Amyloidosis: Diagnosis, Treatment, Outcomes(24), Coagulation, Bradykinin, Polyphosphates, and Angioedema(24), Atrial Fibrillation Management and Outcomes(21), Venous Thromboembolism Diagnosis and Management(15)

Publications149 total

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
JAMA Cardiology·2025Open Access
Abstract 4368185: Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights From the ATTRibute-CM Study
Circulation·2025
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy
Future Cardiology·2025Open Access
Acoramidis Improves Serum Transthyretin Levels in Patients With Wild-type or Variant Transthyretin Amyloid Cardiomyopathy - Results From ATTRibute-CM
Journal of Nuclear Cardiology·2025
Differential Binding Affinities and Kinetics of Transthyretin Stabilizers
Journal of Cardiovascular Pharmacology·2025· 2 citedOpen Access
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
Journal of the American College of Cardiology·2025· 21 citedOpen Access
Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
Journal of Cardiac Failure·2025· 5 citedOpen Access
ACORAMIDIS-MEDIATED EARLY INCREASE IN SERUM TRANSTHYRETIN LEVEL REDUCES CARDIOVASCULAR-RELATED HOSPITALIZATIONS AND MORTALITY: INSIGHTS FROM THE ATTRIBUTE-CM STUDY
Journal of the American College of Cardiology·2025Open Access
PRIMARY ENDPOINT EFFICACY RESULTS IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED SENSITIVITY ANALYSES ADDRESSED TAFAMIDIS USE
Journal of the American College of Cardiology·2025· 1 citedOpen Access
ROBUSTNESS OF PRIMARY ENDPOINT EFFICACY RESULTS WITH ACORAMIDIS IN ATTR-CM IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED NT-PROBNP SENSITIVITY ANALYSES
Journal of the American College of Cardiology·2025Open Access
ACORAMIDIS IMPROVES SERUM TTR LEVELS IN PATIENTS WITH WILD-TYPE OR VARIANT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Journal of the American College of Cardiology·2025· 1 citedOpen Access
IN PARTICIPANTS TREATED WITH ACORAMIDIS, ADDITION OF CONCOMITANT TAFAMIDIS DID NOT FURTHER INCREASE SERUM TTR LEVELS
Journal of the American College of Cardiology·2025Open Access
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Circulation·2024· 41 citedOpen Access
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
European Heart Journal·2024· 2 citedOpen Access
Rationale & Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial: Early Detection Using Cardiac Radionuclide Imaging
Journal of Nuclear Cardiology·2024· 11 cited
Correction to: Validation of a novel western blot assay to monitor patterns and levels of alpha dystroglycan in skeletal muscle of patients with limb girdle muscular dystrophies
Journal of Muscle Research and Cell Motility·2024Open Access
Treatment-related Early Increase in Serum TTR is Associated with Lower Cardiovascular Mortality in ATTR-CM: Insights from ATTRibute-CM PC124 (#292)
2024
Rationale and Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial PC110 (#190)
2024· 1 cited
Early Increase in Serum Transthyretin Level is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM PC130 (#321)
2024
Treatment-related Early Increase in Serum TTR is Associated With Lower Cardiovascular Hospitalization in ATTR-CM: Insights From ATTRibute-CM OC10 (#282)
2024
page 1 of 8Next →

Frequent Co-authors

Stanley J. Hollenbach(14), Robert M. Scarborough(12), Athiwat Hutchaleelaha(9), Bing‐Yan Zhu(9), Zhaozhong J. Jia(8), Paul Wong(8), David R. Phillips(7), Penglie Zhang(7), Francis DeGuzman(6), Jonathan C. Fox(6), Anjali Pandey(6), Yonghong Song(6), Susan Edwards(6), Genmin Lu(5), Greg Coffey(5), Yvonne Pak(5), Wenrong Huang(5), John Woolfrey(5), Ann Arfsten(5), Lane A. Clizbe(5)